Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA PET/MR Guided SBRT-SIB for Prostate Cancer
NCT04402151Phase 2Recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Jun 2020
- Primary completion
- Dec 2027
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by Weill Cornell Medicine. Primary endpoint: Recurrence Free Survival at 24 months. Started Jun 2020; status: recruiting.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04402151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04402151.